Representatives from the Chinese side say they think it likely that Chinese President Xi Jinping will attend the G-20 meeting later this month. But in order to reach a trade...China Economyread more
Software engineers straight out of college often make six-figure salaries, not counting equity compensation.Technologyread more
Wall Street, though, is clamoring for a rate cut, with an 85% chance of a move in July and a 61% probability of three reductions by year's end.The Fedread more
A company spokesperson said the outage was the result of a "an internal technology issue" and was not security related.Retailread more
The flattening of the yield curve is exuding a bad omen for the stock market if history is any guide.Marketsread more
Using MIT's living wage calculator, CNBC Make It mapped out the minimum amount a single parent must earn to meet their basic needs without relying on outside help in every...Earnread more
Hong Kong Chief Executive Carrie Lam announced at a press conference on Saturday that a contentious bill to allow extraditions to mainland China has been put on hold.China Politicsread more
Stratolaunch, the world's largest airplane, which flew once, is up for sale, sources familiar told CNBC.Investing in Spaceread more
Transparency is key… or is it? With the first-ever non-transparent, actively managed exchange-traded fund receiving approval from the SEC, "ETF Edge" goes straight to the...ETF Edgeread more
Mired in a crisis over its best-selling 737 Max plane, Boeing could hand the spotlight over to its rival Airbus at the Paris Air Show.Airlinesread more
A new update to the Apple Watch called watchOS 6 will notify you if the environment you're in is too loud and could damage your hearing.Technologyread more
Self-management and self-discipline are the keys to controlling exorbitant drug-pricing practices, veteran pharmaceutical executive Fred Hassan told CNBC on Thursday.
That, along with leadership like Allergan CEO Brent Saunders starting his social contract with patients, is the way to ensure prices remain low while maintaining the free-price environment that fosters innovation, he said in an interview on "Power Lunch. "
In the last year, most companies have stayed in the single-digit price increase range, he said, meaning things are more in control than they were a year ago.
"Unfortunately, these newer drugs are expensive because innovation is still very expensive. It still costs about $2 million to $3 million on average to bring a new drug to market, and that is still about a million too high," the former Schering-Plough CEO said.
Hassan said the best way to solve the problem is to increase the supply of new drugs, which allows competition in the market to bring the price down.
About one-third of products don't have generics, he said, and "problems occur where a drug stays exclusive for too long."
"When that happens, I think society has every right to push back. ... [T]hat kind of pushback has occurred quite a bit in the past year, and I'm glad to see that pushback occur," said Hassan, who is currently managing director at private equity firm Warburg Pincus.
Despite talk from President Donald Trump on the campaign trail about reducing pricing and several mentions of potential policies, such as allowing consumers to import drugs from other countries with lower prices, the administration has not yet taken concrete steps to address the industry practice.
Hassan prefers it that way.
"The worst solution to all this is to let politicians and bureaucrats get involved with pricing because they really don't know the subject very well and it is a very complex subject," he said.